[go: up one dir, main page]

US3754088A - Piperidone anti-inflammatory agents - Google Patents

Piperidone anti-inflammatory agents Download PDF

Info

Publication number
US3754088A
US3754088A US00144333A US3754088DA US3754088A US 3754088 A US3754088 A US 3754088A US 00144333 A US00144333 A US 00144333A US 3754088D A US3754088D A US 3754088DA US 3754088 A US3754088 A US 3754088A
Authority
US
United States
Prior art keywords
piperidone
methyl
agents
hydrogen
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00144333A
Inventor
B Witzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of US3754088A publication Critical patent/US3754088A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/02—Preparation by ring-closure or hydrogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Definitions

  • This invention relates to a method of treating inflammation in its varying manifestations, utilizing novel antiinflammatory compositions containing piperidones and thiopiperidones.
  • these novel compositions exhibit potent analgesic and antipyretic activity and, therefore, this invention also relates to analgesic and autipyretic methods and compositions. More particularly, this invention is concerned with compositions containing piperidones and thiopiperidones for use in the treatment of inflammation and associated pain and fever.
  • this invention is directed to analgesic and antipyretic methods for the relief and treatment of pain and fever not symptomatically related to an inflammatory indication and compositions utilized therefore.
  • R is hydrogen; alkyl (preferably loweralkyl such as methyl, ethyl, propyl, etc. aralkyl (preferably are loweralkyl such as benzyl, phenethyl, phenylhexyl, phenylpropyl, phenylbutyl and substituted derivatives thereof wherein the substituents include halo, amino, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxy, etc.
  • alkyl preferably loweralkyl such as methyl, ethyl, propyl, etc.
  • aralkyl preferably are loweralkyl such as benzyl, phenethyl, phenylhexyl, phenylpropyl, phenylbutyl and substituted derivatives thereof wherein the substituents include halo, amino, alkyl, alkylthio, alkylsulfinyl, al
  • aryl preferably phenyl or substituted phenyl (such as tolyl, halophenyl, (haloalkyl)phenyl, aminophenyl, alkylamino and dialkylaminophenyl, (alkylthio)phenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, hydroxyphenyl, anisyl, etc.
  • hydroxyalkyl preferably hydroxyloweralkyl such as hydroxyethyl, hydroxypropyl, etc.
  • aminoalkyl preferably aminoloweralkyl such as aminomethyl, aminopropyl, etc.
  • dialkylaminoalkyl preferably diloweralkylamino loweralkyl such as diethylaminoethyl, etc. alkylaminoalkyl (preferably loweralkylaminoloweralkyl); alkylamino (preferably loweralkylamino such as methylamino, ethylamino, etc. carboxyalkyl (preferably carboxyloweralkyl such as carboxymethyl, carboxyethyl, carboxypropyl, etc. haloalkyl (preferably haloloweralkyl such as trifluoromethyl, etc.
  • alkoxyalkyl preferably loweralkoxy lower alkyl such as ethoxymethyl, methoxyethyl, ethoxymethyl, propoxybutyl, etc.
  • acyl such as acetyl, propionyl, benzoyl, cinnamoyl, etc.
  • R R R and R are each hydrogen, alkyl (preferably loweralkyl such as methyl, ethyl, propyl, etc.), hydroxy, cyano, halogen (such as fiuoro, chloro, bromo, etc.), haloalkyl (preferably haloloweralkyl such as fluoromethyl, trichloromethyl, trifluoromethyl, etc.), amino, acylamino (such as acetylamino, propionylamino, benzoylamino, etc.), acyl (such as acetyl, trifiuoroacetyl, propionyl, benzoyl, susbtituted benzoyl, cinnamoyl, nicotinoyl, etc.), carboxy, carboalkoxy (preferably carboloweralkoxy such as carbomethoxy, carboethoxy, etc.), carbamyl, alkyla
  • alkylsulfinyl preferably loweralkylsulfinyl, such as methylsulfinyl, etc.
  • alkylsulfonyl preferably loweralkylsulfonyl, such as methylsulfonyl, etc.
  • alkoxy preferably loweralkoxy such as methoxy, ethoxy, butoxy, etc.
  • hydroxyalkyl preferably hydroxyloweralkyl such as hydroxymethyl, hydroxyethyl, hydroxybutyl, etc.
  • carboxyalkyl preferably carboxyloweralkyl such as carboxymethyl, carboxy ethyl, carboxypropyl, carboxypentyl, etc.
  • trialkylammonium (a quaternary compound, preferably triloweralkylammonium such as trimethylammonium, dimethylethylamrnonium, tripropylammonium, etc. halides, tosylates, etc., carboalkoxyalkyl (preferably carboloweralkoxy loWeralkyl such as carb0 methoxymethyl, carboethoxypropyl, carbomethoxypentyl, etc. alkoxyalkyl (preferably loweralkoxy loweralkyl such as methoxymethyl, ethoxy propyl, methoxypentyl, ethoxymethyl, etc.
  • acyloxy such as acetoxy, propionyloxy, butyroyloxy benzoyloxy, substituted benzoyloxy, nicotinoyloxy, etc. substituted carbamyl (such as monoand dialkyl carbamyl and monoand diarylcarbamyl such as dimethylcarbamyl, phenylcarbamyl, methylethylcarbamyl, etc.
  • EXAMPLE 1 4-t-butyl-2-piperidone A mixture of 4-t-butyl-2[lH]-pyridone (3.0 g., 0.02 m.), acetic acid (glacial, 60 ml.) and platinum oxide (0.7 g.) is reacted in a 40 p.s.i. hydrogen atmosphere until hydrogen uptake ceases. The mixture is then filtered, the acetic acid removed in vacuo, toluene (125 ml.) is added, the toluene removed in vacuo, and the residue recrystallized from ether (boiling to ca. 50 ml.) to yield 4-t-butyl-2-piperidone, M.P. 134-136 C.
  • Representative piperidones prepared from the corresponding pyridones by this procedure include 6-methyl-4- trifluoromethyl-2-piperidone, M.P. 106111 C.; 4-cyclohexyl-2-piperidone (from 4-phenyl 2 pyridone), M.P. l61-162 C.; 3 cyclohexyl 2 piperidone, M.P. 117.0- 118.5 C.; S-trifluoromethyl-Z-piperidone, M.P. 136-139 C.; 6-ethyl-4-methyl-2-piperidone, M.P. 7682 C.; 4- ethyI-Z-piperidone, M.P. 3745); 6-ethyl-4-methyl-2- piperidone (M.P. IOU-103 C.), 4,6-dimethyl-2 -piperidone, M.P. 125-126 C.
  • EXAMPLE 2 4-methyl-2-piperidone and 3-dimethylamino-4-methyl- 2-piperidone
  • a mixture of 3 dimethylamino 4 methyl 2[1H]- pyridone (2.3 g., 0.015 m.), acetic acid (glacial, 60 ml.) and platinum oxide (1.0 g.) is reacted in a 40 p.s.i. hy drogen atmosphere until hydrogen uptake is 12% over theory.
  • the mixture is then filtered, the acetic acid removed in vacuo, the oily residue taken up in chloroform, washed with dilute sodium bicarbonate solution, the chloroform layer dried, filtered and concentrated to 2.6 g.
  • EXAMPLE 3 3-dimethylamino-4-methyl-2-piperidone
  • a mixture of 3-bromo-4-methyl-2-piperidone (0.01 m.), 40% aqueous dimethylamine ml.), and dimethylformamide (25 ml.) is heated at 140 C. for 18 hours in a sealed tube.
  • the cooled mixture is concentrated in vacuo, the residue partitioned between chloroform-dilute sodium bicarbonate solution, the layers separated, the aqueous layer re-extracted With chloroform, and the chloroform extracts combined, dried and concentrated to a residue.
  • EXAMPLE 4 4-methyl-3-trimethylammonium-Z-piperidone iodide 3-dimethylamino-4-methyl-2-piperidone is boiled in excess methyliodide, filtered, and the solution boiled down to a small volume and allowed to stand several days. Filtering yields 4 methyl 3 trimethylammonium 2- piperidone iodide.
  • EXAMPLE 5 4-methyl-S-methylsulfinyl-Z-piperidone- To an ice-cooled solution of 4-methyl-5-methylmercapto-2-piperidone (0.01 m.) in methanol-acetone is added a solution of sodium metaperiodate (0.012 m.) in a minimum of water. The mixture is stirred below C. until precipitation of sodium iodate is completed, the iodate removed by filtration, the solvents removed in vacuo (below room temperature), and the residue taken up in chloroform, the chloroform dried, concentrated in vacuo and the material thus obtained chromatographed on a silica gel column using a methanol-methylene chloride system (v./v. 0-10% methanol) as eluant to yield 4-methyl-5-methylsulfinyl-2-piperidone.
  • a solution of sodium metaperiodate 0.012 m.
  • the piperidones and thiopiperidones of the invention possess a high degree of anti-inflammatory, analgesic and antipyretic activity. They are of value in the treatment of arthritic and dermatological disorders or like conditions responsive to anti-inflammatory drugs. In general they are indicated for a wide variety of conditions where one or more of the symptoms of inflammation, fever and pain are manifested. Included within this category are diseases such as rheumatoid arthritis, osteo arthritis, gout, infectious arthritis and rheumatic fever. As indicated above the compounds utilized in the practice of the invention also possess as useful degree of analgesic and antipyretic activity.
  • the compounds of the invention may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • the compounds of the invention are effective in the treatment of humans.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmeth'ylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturallyoccurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethyelne stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid parafiin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard parafiin or cetyl alcohol.
  • Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil, for example liquid paralfin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan mono-oleate.
  • the emulsions may also contain sweening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • Suitable vehicles and solvents that may be employed are water, Ringers solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic monoor diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectibles.
  • the compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • creams, ointments, jellies, solutions or suspensions etc, containing the anti-inflammatory agents are employed.
  • Dosage levels of the order of 20 mg. to 7 grams per day are useful in the treatment of the above indicated conditions.
  • inflammation is efiectively treated and anti-pyretic and analgesic activity manifested by the administration from about .3 to 100 milligrams of the compound per kilogram of body weight per day.
  • Advantageously from about 2 mg. to about 50 mg. per kilogram of body weight and especially from about 4 mg. to about 20 mg./kg. per daily dosage produce highly efiective results.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 5 mg. to 5 grams of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about percent of the total composition.
  • Dosage unit forms will generally contain between from about 25 mg. to about 500 mg. of active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • EXAMPLE 1 A mixture of 250 parts of 4-methyl-2-piperidone and 25 parts of lactose is granulated with suitable water, and to this added parts of maize starch. The mass is passed through a 16 mesh screen. The granules are dried at a temperature below 60 C. The dry granules are passed through a 16 mesh screen, and mixed with 3.8 parts of magnesium stearate. They are then compressed into tablets suitable for oral administration.
  • the 4-methyl-2-piperidone used in the foregoing example may be replaced by 25, 100, 250, or 500 parts of other piperidones or thiopiperidones of this invention to produce tablets suitable for oral administration as an anti-inflammatory, antipyretic and/or analgesic accordmg to the method of this invention.
  • EXAMPLE 2 A mixture of 50 parts of 4-ethyl-2-piperidone, 3 parts of the calcium salt of lignin sulphonic acid, and 237 parts of water is ball-milled until the size of substantially all of the particles of 4-ethyl-2-piperidone is less than 10 nucrons. The suspension is diluted with a solution contaming 3 parts of sodium carboxymethylcellulose and 0.9 part of the butyl ester of p-hydroxybenzoic acid in 300 parts of water. There is thus obtained an aqueous suspension suitable for oral administration for therapeutic purposes.
  • EXAMPLE 3 A mixture of 250 parts of 3-amino-4-methyl-2-piperidone, 200 parts of maize starch and 30 parts of alginic acid is mixed with a sufiicient quantity of 10% aqueous paste of maize starch, and granulated. The granules are dried in a current of warm air and the dry granules are then passed through a 16-mesh screen, mixed with 6 parts of magnesium stearate and compressed into tablet form to obtain tablets suitable for oral administration.
  • the powdered thiopiperidone is mixed with the starchlactose mixture followed by the talc and calcium stearate. The final mixture is then encapsulated in the usual manner.
  • Capsules containing 10, 25, 50, and 100 mg. of piperidone are also prepared by substituting 100, 250, 500 and 1000 gm. for 2500 gm. in the above formulation.
  • Soft elastic capsules One-piece soft elastic capsules for oral use, each containing 200 mg. of piperidone or thiopiperidone are prepared in the usual manner by first dispersing the powdered active material in suflicient corn oil to render the material capsulatable.
  • Aqueous suspension An aqueous suspension for oral use containing in each 5 ml., 1 gram of piperidone is prepared from the following ingredients:
  • a method of treating humans and animals exhibiting at least one of the symptoms of pain, fever and infiamma tion which comprises the administration to said humans and animals of from about 20 mg. to 7 grams of a compound having the formula:
  • R is hydrogen, loweralkyl, hydroxyloweralkyl, haloloweralkyl or alkoxyloweralkyl
  • R R R and R are each hydrogen, loweralkyl, hydroxy, halogen, haloloweralkyl, loweralkoxy, hydroxyloweralkyl, or alkoxyloweralkyl.
  • R is hydrogen or loweralkyl; R is loweralkoxy, hydroxy or halogen; R is loweralkyl, hydrogen, hydroxyloweralkyl haloloweralkyl; R is hydrogen or loweralkyl; R is hydrogen or loweralkyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION, PAIN AND FEVER EMPLOYING PIPERIDONES AND THIROPIPERIDONES.

Description

United States Patent "ice 3,754,088 PIPERIDONE ANTI-INFLANIMATORY AGENTS Bruce E. Witzel, Westfield, N.J., assignor to Merck & Co., Inc., Rahway, NJ. No Drawing. Filed May 17, 1971, Ser. No. 144,333 Int. Cl. A01n 27/00 US. Cl. 424267 7 Claims ABSTRACT OF THE DISCLOSURE Methods and compositions for the treatment of inflammation, pain and fever employing piperidones and thiopiperidones.
This invention relates to a method of treating inflammation in its varying manifestations, utilizing novel antiinflammatory compositions containing piperidones and thiopiperidones. In addition, these novel compositions exhibit potent analgesic and antipyretic activity and, therefore, this invention also relates to analgesic and autipyretic methods and compositions. More particularly, this invention is concerned with compositions containing piperidones and thiopiperidones for use in the treatment of inflammation and associated pain and fever. Furthermore, this invention is directed to analgesic and antipyretic methods for the relief and treatment of pain and fever not symptomatically related to an inflammatory indication and compositions utilized therefore.
The piperidones and thiopiperidones employed in the treatment of a condition symptomatically evidenced by pain, fever and inflammation, either as an essential or concomitant phenomena of the condition are represented by the following formulas:
and 1 Rs N O Rs N S in which R is hydrogen; alkyl (preferably loweralkyl such as methyl, ethyl, propyl, etc. aralkyl (preferably are loweralkyl such as benzyl, phenethyl, phenylhexyl, phenylpropyl, phenylbutyl and substituted derivatives thereof wherein the substituents include halo, amino, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxy, etc. aryl (preferably phenyl) or substituted phenyl (such as tolyl, halophenyl, (haloalkyl)phenyl, aminophenyl, alkylamino and dialkylaminophenyl, (alkylthio)phenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, hydroxyphenyl, anisyl, etc. hydroxyalkyl (preferably hydroxyloweralkyl such as hydroxyethyl, hydroxypropyl, etc. aminoalkyl (preferably aminoloweralkyl such as aminomethyl, aminopropyl, etc. dialkylaminoalkyl (preferably diloweralkylamino loweralkyl such as diethylaminoethyl, etc. alkylaminoalkyl (preferably loweralkylaminoloweralkyl); alkylamino (preferably loweralkylamino such as methylamino, ethylamino, etc. carboxyalkyl (preferably carboxyloweralkyl such as carboxymethyl, carboxyethyl, carboxypropyl, etc. haloalkyl (preferably haloloweralkyl such as trifluoromethyl, etc. alkoxyalkyl (preferably loweralkoxy lower alkyl such as ethoxymethyl, methoxyethyl, ethoxymethyl, propoxybutyl, etc. acyl, such as acetyl, propionyl, benzoyl, cinnamoyl, etc.
3,754,088 Patented Aug. 21, 1973 R R R and R are each hydrogen, alkyl (preferably loweralkyl such as methyl, ethyl, propyl, etc.), hydroxy, cyano, halogen (such as fiuoro, chloro, bromo, etc.), haloalkyl (preferably haloloweralkyl such as fluoromethyl, trichloromethyl, trifluoromethyl, etc.), amino, acylamino (such as acetylamino, propionylamino, benzoylamino, etc.), acyl (such as acetyl, trifiuoroacetyl, propionyl, benzoyl, susbtituted benzoyl, cinnamoyl, nicotinoyl, etc.), carboxy, carboalkoxy (preferably carboloweralkoxy such as carbomethoxy, carboethoxy, etc.), carbamyl, alkylamino (preferably loweralkylamino such as methylamino, ethylamino, etc.), and dialkylamino (preferably diloweralkylamino such as dimethylamino, diethylamino, etc.), alkylmercapto (preferably loweralkylmercapto, such as methylmercapto, etc. alkylsulfinyl (preferably loweralkylsulfinyl, such as methylsulfinyl, etc.), alkylsulfonyl (preferably loweralkylsulfonyl, such as methylsulfonyl, etc.), alkoxy (preferably loweralkoxy such as methoxy, ethoxy, butoxy, etc. hydroxyalkyl (preferably hydroxyloweralkyl such as hydroxymethyl, hydroxyethyl, hydroxybutyl, etc. carboxyalkyl (preferably carboxyloweralkyl such as carboxymethyl, carboxy ethyl, carboxypropyl, carboxypentyl, etc. trialkylammonium (a quaternary compound, preferably triloweralkylammonium such as trimethylammonium, dimethylethylamrnonium, tripropylammonium, etc. halides, tosylates, etc., carboalkoxyalkyl (preferably carboloweralkoxy loWeralkyl such as carb0 methoxymethyl, carboethoxypropyl, carbomethoxypentyl, etc. alkoxyalkyl (preferably loweralkoxy loweralkyl such as methoxymethyl, ethoxy propyl, methoxypentyl, ethoxymethyl, etc. aminoalkyl (preferably aminoloweralkyl such as aminomethyl, aminopropyl, aminopentyi, etc. ),alkylarninoa1kyl (preferably loweralkylaminoloweralkyl such as methylaminoethyl, ethylaminopropyl, methylaminopropyl, methylaminopentyl, etc. dialkylaminoalkyl (preferably diloweralkylaminoloweralkyl, dimethylaminoethyl, diethylaminopropyl, methylethylaminopentyl, etc. acyloxy (such as acetoxy, propionyloxy, butyroyloxy benzoyloxy, substituted benzoyloxy, nicotinoyloxy, etc. substituted carbamyl (such as monoand dialkyl carbamyl and monoand diarylcarbamyl such as dimethylcarbamyl, phenylcarbamyl, methylethylcarbamyl, etc.
In its preferred aspects this invention relates to the compounds of Formula I wherein R =hydrogen, alkyl, aralkyl, aryl, dialkylaminoalkyl, carboxyalkyl; R =amino, alkylamino, dialkylamino, alkoxy, hydroxy, cyano, halogen, trialkylammonium; R.,=alkyl, hydrogen, hydroxyalkyl, carboxyalkyl, carboxy, acylamino, haloalkyl, alkylamino, alkylaminoalkyl; R =hydrogen, alkyl, dialkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, acyl; R =hydrogen, alkyl.
Representative of the compounds included within the scope of the invention include the following:
4-methyl-2-piperidone 4-ethy1-2-piperidone 4-i-propyl-2-piperidone 4-n-propyl-2-piperidone 4-n-butyl-2-piperidone 4-t-butyl-2-piperidone 3-amino-4methyl-2-piperidone 3-mcthylamino-4-methyl-Z-piperidone 5-dimethylamino-4-methyl-2-piperidone 3-dimethylamino-4-methyl-2-piperidone 3-dimethylamino-4-ethyl-2-piperidone 6-ethyl-2-piperidone 3-methoxy-4-methyl-2-piperidone corresponding lactone, and partial reduction of substituted glutarimides are useful procedures for these compounds.
EXAMPLE 1 4-t-butyl-2-piperidone A mixture of 4-t-butyl-2[lH]-pyridone (3.0 g., 0.02 m.), acetic acid (glacial, 60 ml.) and platinum oxide (0.7 g.) is reacted in a 40 p.s.i. hydrogen atmosphere until hydrogen uptake ceases. The mixture is then filtered, the acetic acid removed in vacuo, toluene (125 ml.) is added, the toluene removed in vacuo, and the residue recrystallized from ether (boiling to ca. 50 ml.) to yield 4-t-butyl-2-piperidone, M.P. 134-136 C.
Representative piperidones prepared from the corresponding pyridones by this procedure include 6-methyl-4- trifluoromethyl-2-piperidone, M.P. 106111 C.; 4-cyclohexyl-2-piperidone (from 4-phenyl 2 pyridone), M.P. l61-162 C.; 3 cyclohexyl 2 piperidone, M.P. 117.0- 118.5 C.; S-trifluoromethyl-Z-piperidone, M.P. 136-139 C.; 6-ethyl-4-methyl-2-piperidone, M.P. 7682 C.; 4- ethyI-Z-piperidone, M.P. 3745); 6-ethyl-4-methyl-2- piperidone (M.P. IOU-103 C.), 4,6-dimethyl-2 -piperidone, M.P. 125-126 C.
EXAMPLE 2 4-methyl-2-piperidone and 3-dimethylamino-4-methyl- 2-piperidone A mixture of 3 dimethylamino 4 methyl 2[1H]- pyridone (2.3 g., 0.015 m.), acetic acid (glacial, 60 ml.) and platinum oxide (1.0 g.) is reacted in a 40 p.s.i. hy drogen atmosphere until hydrogen uptake is 12% over theory. The mixture is then filtered, the acetic acid removed in vacuo, the oily residue taken up in chloroform, washed with dilute sodium bicarbonate solution, the chloroform layer dried, filtered and concentrated to 2.6 g. of an oil, which is then chromatographed on a 125 g. silica gel column using a methanol-methylene chloride system (v./v. 03% methanol) to yield 4-methyl-2-piperidone and 3-dimethylamino-4-methyl 2 piperidone. Recrystallization of either from ether yields pure material, M.P. 87-89.5- and 144.5146.5 C., respectively.
EXAMPLE 3 3-dimethylamino-4-methyl-2-piperidone A mixture of 3-bromo-4-methyl-2-piperidone (0.01 m.), 40% aqueous dimethylamine ml.), and dimethylformamide (25 ml.) is heated at 140 C. for 18 hours in a sealed tube. The cooled mixture is concentrated in vacuo, the residue partitioned between chloroform-dilute sodium bicarbonate solution, the layers separated, the aqueous layer re-extracted With chloroform, and the chloroform extracts combined, dried and concentrated to a residue.
Chromatography of this residue on a silica gel column using a methanol-methylene chloride system (v./V. 05%- methanol) as eluant yields 3 dimethylamino-4-methyl- 2-piperidone.
EXAMPLE 4 4-methyl-3-trimethylammonium-Z-piperidone iodide 3-dimethylamino-4-methyl-2-piperidone is boiled in excess methyliodide, filtered, and the solution boiled down to a small volume and allowed to stand several days. Filtering yields 4 methyl 3 trimethylammonium 2- piperidone iodide.
EXAMPLE 5 4-methyl-S-methylsulfinyl-Z-piperidone- To an ice-cooled solution of 4-methyl-5-methylmercapto-2-piperidone (0.01 m.) in methanol-acetone is added a solution of sodium metaperiodate (0.012 m.) in a minimum of water. The mixture is stirred below C. until precipitation of sodium iodate is completed, the iodate removed by filtration, the solvents removed in vacuo (below room temperature), and the residue taken up in chloroform, the chloroform dried, concentrated in vacuo and the material thus obtained chromatographed on a silica gel column using a methanol-methylene chloride system (v./v. 0-10% methanol) as eluant to yield 4-methyl-5-methylsulfinyl-2-piperidone.
Use of excess metaperiodate at elevated temperatures or use of hydrogen peroxide in acetic acid, followed by chromatography yields the corresponding sulfone, 4- methyl-S-methylsulfonyl-Z-piperidone.
The piperidones and thiopiperidones of the invention possess a high degree of anti-inflammatory, analgesic and antipyretic activity. They are of value in the treatment of arthritic and dermatological disorders or like conditions responsive to anti-inflammatory drugs. In general they are indicated for a wide variety of conditions where one or more of the symptoms of inflammation, fever and pain are manifested. Included within this category are diseases such as rheumatoid arthritis, osteo arthritis, gout, infectious arthritis and rheumatic fever. As indicated above the compounds utilized in the practice of the invention also possess as useful degree of analgesic and antipyretic activity.
For these purposes the compounds of the invention may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warmblooded animals such as mice, rats, horses, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide a pharmaceutically elegant and palatable preparation. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, maize starch, or alginic acid; binding agents, for example starch, gelatine or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate above or with a wax may be employed.
Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, for example arachis oil, peanut oil, liquid parafiin or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmeth'ylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturallyoccurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethyelne stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan mono-oleate. The said aqueous suspensions may also contain one or more preservations, for example ethyl, or n-propyl, p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as scurose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid parafiin. The oily suspensions may contain a thickening agent, for example beeswax, hard parafiin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil, for example liquid paralfin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan mono-oleate. The emulsions may also contain sweening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringers solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic monoor diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectibles.
The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions etc, containing the anti-inflammatory agents are employed.
Dosage levels of the order of 20 mg. to 7 grams per day are useful in the treatment of the above indicated conditions. For example, inflammation is efiectively treated and anti-pyretic and analgesic activity manifested by the administration from about .3 to 100 milligrams of the compound per kilogram of body weight per day. Advantageously from about 2 mg. to about 50 mg. per kilogram of body weight and especially from about 4 mg. to about 20 mg./kg. per daily dosage produce highly efiective results.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example a formulation intended for the oral administration of humans may contain from 5 mg. to 5 grams of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about percent of the total composition. Dosage unit forms will generally contain between from about 25 mg. to about 500 mg. of active ingredient.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
The following are illustrative of the techniques that may be employed in the preparation of pharmaceutical formulations to be utilized in the practice of the invention:
EXAMPLE 1 A mixture of 250 parts of 4-methyl-2-piperidone and 25 parts of lactose is granulated with suitable water, and to this added parts of maize starch. The mass is passed through a 16 mesh screen. The granules are dried at a temperature below 60 C. The dry granules are passed through a 16 mesh screen, and mixed with 3.8 parts of magnesium stearate. They are then compressed into tablets suitable for oral administration.
The 4-methyl-2-piperidone used in the foregoing example may be replaced by 25, 100, 250, or 500 parts of other piperidones or thiopiperidones of this invention to produce tablets suitable for oral administration as an anti-inflammatory, antipyretic and/or analgesic accordmg to the method of this invention.
EXAMPLE 2 A mixture of 50 parts of 4-ethyl-2-piperidone, 3 parts of the calcium salt of lignin sulphonic acid, and 237 parts of water is ball-milled until the size of substantially all of the particles of 4-ethyl-2-piperidone is less than 10 nucrons. The suspension is diluted with a solution contaming 3 parts of sodium carboxymethylcellulose and 0.9 part of the butyl ester of p-hydroxybenzoic acid in 300 parts of water. There is thus obtained an aqueous suspension suitable for oral administration for therapeutic purposes.
EXAMPLE 3 A mixture of 250 parts of 3-amino-4-methyl-2-piperidone, 200 parts of maize starch and 30 parts of alginic acid is mixed with a sufiicient quantity of 10% aqueous paste of maize starch, and granulated. The granules are dried in a current of warm air and the dry granules are then passed through a 16-mesh screen, mixed with 6 parts of magnesium stearate and compressed into tablet form to obtain tablets suitable for oral administration.
9 EXAMPLE 4 (1) Tablets.10,000 scored tablets for oral use, each containing 500 mg. of piperidone are prepared from the following ingredients:
Gm. 3-methoxy-4-methyl-2-piperidone 5000 Starch, U.S.P. 350 Talc, U.S.P. 250 Calcium stearate 35 Gm. 4-carboxy-2-thiopiperidone 2500 Lactose, U.S.P. 1000 Starch, U.S.P 300 Talc. U.S.P. 65 Calcium stearate 25 The powdered thiopiperidone is mixed with the starchlactose mixture followed by the talc and calcium stearate. The final mixture is then encapsulated in the usual manner. Capsules containing 10, 25, 50, and 100 mg. of piperidone are also prepared by substituting 100, 250, 500 and 1000 gm. for 2500 gm. in the above formulation.
(3) Soft elastic capsules.One-piece soft elastic capsules for oral use, each containing 200 mg. of piperidone or thiopiperidone are prepared in the usual manner by first dispersing the powdered active material in suflicient corn oil to render the material capsulatable.
(4) Aqueous suspension.An aqueous suspension for oral use containing in each 5 ml., 1 gram of piperidone is prepared from the following ingredients:
Deionized water, q.s. to 10,000 mg.
What is claimed is:
1. A method of treating humans and animals exhibiting at least one of the symptoms of pain, fever and infiamma tion which comprises the administration to said humans and animals of from about 20 mg. to 7 grams of a compound having the formula:
in which R is hydrogen, loweralkyl, hydroxyloweralkyl, haloloweralkyl or alkoxyloweralkyl;
R R R and R are each hydrogen, loweralkyl, hydroxy, halogen, haloloweralkyl, loweralkoxy, hydroxyloweralkyl, or alkoxyloweralkyl.
2. The method of claim 1 wherein R is hydrogen or loweralkyl; R is loweralkoxy, hydroxy or halogen; R is loweralkyl, hydrogen, hydroxyloweralkyl haloloweralkyl; R is hydrogen or loweralkyl; R is hydrogen or loweralkyl.
3. The method of claim 2 wherein the compound is selected from the group consisting of 4-methyl-2-piperidone, 4-ethyl-2-piperidone, 4-i-propyl-2-piperidone, 4-n-propyl- Z-piperidone, 4-n-butyl-2-piperidone, 4-t-butyl-2-piperidone, 6-ethyl-2-piperidone, 3-methoxy-4-methyl-2-piperidone, 3-hydroxy-4-methyl-2-piperidone, 4-hydroxymethyl- 2-piperidone, 4-hydroxyethyl-2-piperidone, 3-fluoro-4- methyl-Z-piperidone, 3-chloro-4-methyl-2-piperidone and S-fluoro-4,S-dimethyl-Z-piperidone.
4. The method of claim 3 wherein the compound is 4- methyl-Z-piperidone.
5. The method of claim 3 wherein the compound is 4- ethyl-Z-piperidone.
6. The method of claim 2 wherein the compound is 4-n-propyl-2-piperidone.
7. The method of claim 2 wherein the compound is 4-n-butyl-2-piperidone.
References Cited Chemical Abstracts 63:13199b (1965). Chemical Abstracts 53:2l940h-21941e (1959). Chemical Abstracts 61:3075f (1964). Chemical Abstracts 63:8920e (1965).
ALBERT T. MEYERS, Primary Examiner L. SCHENKMAN, Assistant Examiner TED STATES PATENT FCE QEIREEECE 'F Efi'li Patent 3,7s4n0ss Dated Auguqt 91 1972 Inventor(s) Bruce E, Witzel it is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
In Claim 6,, "The method of claim 2. o a
should read "The method of claim 3. a
In Claim 7, "The method of claim 2 Q should lead "The method of claim 3. c
Signed and sealed this 19th day of March 1974.
(SEAL) Attest:
C. MARSHALL DANN RD M.FLETCHER JR. EDWA 9 Commissioner of Patents Attesting Officer
US00144333A 1971-05-17 1971-05-17 Piperidone anti-inflammatory agents Expired - Lifetime US3754088A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14433371A 1971-05-17 1971-05-17

Publications (1)

Publication Number Publication Date
US3754088A true US3754088A (en) 1973-08-21

Family

ID=22508123

Family Applications (1)

Application Number Title Priority Date Filing Date
US00144333A Expired - Lifetime US3754088A (en) 1971-05-17 1971-05-17 Piperidone anti-inflammatory agents

Country Status (1)

Country Link
US (1) US3754088A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205174A (en) * 1978-01-11 1980-05-27 Lonza, Ltd. Process for the production of 6-substituted 4-methyl-2-pyridones
US4451469A (en) * 1982-12-16 1984-05-29 Sterling Drug Inc. Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics
US4725607A (en) * 1985-09-19 1988-02-16 Imperial Chemical Industries Plc Aryl pyridones and insecticidal use thereof
WO1988002985A1 (en) * 1986-10-24 1988-05-05 Gaf Corporation Quaternized nitrogen containing compounds
FR2607809A1 (en) * 1986-12-03 1988-06-10 Tanabe Seiyaku Co LACTAM DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5229518A (en) * 1991-03-06 1993-07-20 Abbott Laboratories Isomerically pure 2-piperidone compounds
WO1996002504A1 (en) * 1994-07-15 1996-02-01 Dr. Karl Thomae Gmbh 6-biphenyloxymethyl-4-carboxy-2-piperidinones, drugs containing these compounds and process for their preparation
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
WO2020229199A1 (en) * 2019-05-14 2020-11-19 Unilever N.V. 2(1h)-pyridinones and their use to treat inflammatory conditions
US11826453B2 (en) 2019-05-14 2023-11-28 Conopco, Inc. Hair care composition comprising piroctone olamine

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205174A (en) * 1978-01-11 1980-05-27 Lonza, Ltd. Process for the production of 6-substituted 4-methyl-2-pyridones
US4451469A (en) * 1982-12-16 1984-05-29 Sterling Drug Inc. Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics
US4725607A (en) * 1985-09-19 1988-02-16 Imperial Chemical Industries Plc Aryl pyridones and insecticidal use thereof
WO1988002985A1 (en) * 1986-10-24 1988-05-05 Gaf Corporation Quaternized nitrogen containing compounds
FR2607809A1 (en) * 1986-12-03 1988-06-10 Tanabe Seiyaku Co LACTAM DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
EP0270093A3 (en) * 1986-12-03 1989-12-27 Tanabe Seiyaku Co., Ltd. Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties
US5229518A (en) * 1991-03-06 1993-07-20 Abbott Laboratories Isomerically pure 2-piperidone compounds
WO1996002504A1 (en) * 1994-07-15 1996-02-01 Dr. Karl Thomae Gmbh 6-biphenyloxymethyl-4-carboxy-2-piperidinones, drugs containing these compounds and process for their preparation
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
US6066666A (en) * 1995-06-05 2000-05-23 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
WO2020229199A1 (en) * 2019-05-14 2020-11-19 Unilever N.V. 2(1h)-pyridinones and their use to treat inflammatory conditions
US11826453B2 (en) 2019-05-14 2023-11-28 Conopco, Inc. Hair care composition comprising piroctone olamine
JP7451564B2 (en) 2019-05-14 2024-03-18 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ 2(1H)-pyridinones and their use for treating inflammatory conditions
US12215084B2 (en) 2019-05-14 2025-02-04 Conopco, Inc. 2(1H)-pyridinones and their use to treat inflammatory conditions

Similar Documents

Publication Publication Date Title
US3655897A (en) Anti-inflammatory agents
US3654291A (en) Certain 3-amino-2(1h)-pyridones
US3835143A (en) Certain 2(1h) pyridinethiones
US3957764A (en) 6-aminopenicillanic acid derivatives
US3718743A (en) 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones in compositions and methods for treating pain, fever and inflammation
HK59188A (en) Use of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-beta-methoxy ethylester-5-isopropylester for the preparation of cerebrally active drugs
US3754088A (en) Piperidone anti-inflammatory agents
US3644626A (en) Novel pyridones in compositions and methods for treating inflammation pain and fever
US3689567A (en) Benzyl methyl sulfones and process for preparing same
US3754005A (en) Thiaxanthene derivatives
DE69012650T2 (en) Piperidine derivative, process for its preparation and pharmaceutical composition containing the same.
US3637803A (en) Alkyl methylsulfonylalkyl benzoates
US3846553A (en) 3-substituted-2-pyridones in the treatment of pain, fever or inflammation
EP0104959B1 (en) 4-quinolone derivatives
US3711608A (en) The treatment of pain, fever and inflammation with benzimidazoles
US3792170A (en) Novel alkylsulfinyl derivatives for pain,fever and inflammation
US3814771A (en) 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones
SU1318163A3 (en) Method for producing 6-substituted 6h-dibenzo (b,d) pyran derivatives or pharmaceutically or veterinarily acceptable salts thereof
US3892769A (en) Acetaminophen esters of aryl salicylic acids
US3674794A (en) Certain-3-pyridine-sulfonamide derivatives
EP0027895A1 (en) 1-(2-(Alkyl and arylsulfonyl)-2-propenyl and propyl) substituted piperidines and pharmaceutical and antimicrobial compositions comprising the same
US3830922A (en) Thiopiperidone antiinflammatory agents
US4256752A (en) Treatment of ulcers with acylated aminoalkyl cyanoguanidines containing a heterocyclic residue
DE3216843A1 (en) THIOMETHYLPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE2601262A1 (en) 1-R-4- (OMEGA-SUBSTITUTED ALKYL) -3, 3-DIPHENYL-2-PYRROLIDINONE AND THE METHOD FOR THEIR MANUFACTURING